Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if 4 escalating doses during 20 weeks of NP031112
are safe and tolerated in patients with Alzheimer´s disease.